Laith Alhuneafat, Omar Obeidat, Mohammed Ayyad, Ahmad Alayyat, Waqas Rasheed, Ahmad Maaita, Fares Ghanem, Zaid Shahrori, Anas Alameh, Ahmad Al-Abdouh, Pedro Villablanca, Ahmad Jabri
{"title":"Inpatient Tricuspid Valve Transcatheter and Surgical Inpatient Outcomes: A Propensity Matched Analysis.","authors":"Laith Alhuneafat, Omar Obeidat, Mohammed Ayyad, Ahmad Alayyat, Waqas Rasheed, Ahmad Maaita, Fares Ghanem, Zaid Shahrori, Anas Alameh, Ahmad Al-Abdouh, Pedro Villablanca, Ahmad Jabri","doi":"10.1177/00033197251379122","DOIUrl":null,"url":null,"abstract":"<p><p>Tricuspid regurgitation (TR) is a common valvular disorder associated with significant morbidity and mortality. While surgical repair (STVr) and replacement (STVR) are established treatments, transcatheter tricuspid valve interventions (TTVI) have emerged as less invasive alternatives. The present study compared inpatient outcomes of TTVI, STVr, and STVR using data from the National Inpatient Sample (2011-2020). A retrospective analysis identified 1830 TTVI, 76 747 STVr, and 19 625 STVR procedures. After propensity score matching, 1655 TTVI-STVr and 1286 TTVI-STVR patient pairs were included. Compared with surgery, TTVI was associated with significantly lower in-hospital mortality (2.4% vs 7.0% STVr; 2.3% vs 11.6% STVR; <i>P</i> < .001), shorter hospital stays (6.9 vs 15.6 days STVr; 7.2 vs 17.6 days STVR; <i>P</i> < .001), and reduced costs. TTVI was associated with lower in-hospital mortality, fewer complications, and shorter hospital stays compared with surgical interventions in this analysis. Given the limitations of retrospective studies, including selection bias and lack of long-term follow-up, these findings require cautious interpretation. Prospective studies are needed to compare the efficacy and durability of TTVI versus surgery for TR.</p>","PeriodicalId":8264,"journal":{"name":"Angiology","volume":" ","pages":"999-1006"},"PeriodicalIF":2.7000,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Angiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/00033197251379122","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/10/7 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}
引用次数: 0
Abstract
Tricuspid regurgitation (TR) is a common valvular disorder associated with significant morbidity and mortality. While surgical repair (STVr) and replacement (STVR) are established treatments, transcatheter tricuspid valve interventions (TTVI) have emerged as less invasive alternatives. The present study compared inpatient outcomes of TTVI, STVr, and STVR using data from the National Inpatient Sample (2011-2020). A retrospective analysis identified 1830 TTVI, 76 747 STVr, and 19 625 STVR procedures. After propensity score matching, 1655 TTVI-STVr and 1286 TTVI-STVR patient pairs were included. Compared with surgery, TTVI was associated with significantly lower in-hospital mortality (2.4% vs 7.0% STVr; 2.3% vs 11.6% STVR; P < .001), shorter hospital stays (6.9 vs 15.6 days STVr; 7.2 vs 17.6 days STVR; P < .001), and reduced costs. TTVI was associated with lower in-hospital mortality, fewer complications, and shorter hospital stays compared with surgical interventions in this analysis. Given the limitations of retrospective studies, including selection bias and lack of long-term follow-up, these findings require cautious interpretation. Prospective studies are needed to compare the efficacy and durability of TTVI versus surgery for TR.
期刊介绍:
A presentation of original, peer-reviewed original articles, review and case reports relative to all phases of all vascular diseases, Angiology (ANG) offers more than a typical cardiology journal. With approximately 1000 pages per year covering diagnostic methods, therapeutic approaches, and clinical and laboratory research, ANG is among the most informative publications in the field of peripheral vascular and cardiovascular diseases. This journal is a member of the Committee on Publication Ethics (COPE). Average time from submission to first decision: 13 days